Fund of the week: OrbiMed Royalty & Credit Opportunities
Executive Summary
OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the healthcare sector. Since launching its first dedicated royalty/credit fund in 2011, OrbiMed has steadily expanded this business, raising successive funds and deploying capital into royalty monetizations and credit deals across biopharma, medical devices, diagnostics, and more. This in-depth report examines OrbiMed's Royalty & Credit Opportunities ("RCO") funds – their history, structure, key deals (including the latest as of September 2025), geographic and therapeutic focus – and provides a balanced financial analysis (both optimistic blue team and critical red team perspectives) for a financial audience.
History and Growth of OrbiMed's RCO Funds
OrbiMed is one of the world's largest healthcare-focused investment firms, managing over $17 billion in assets across public equity, venture/private equity, and royalty/credit strategies. The RCO initiative began in 2011 when OrbiMed launched its first dedicated healthcare royalty/credit fund (sometimes called "Royalty Opportunities").
Table 1: OrbiMed RCO Fund Evolution Timeline
| Fund | Year | Size | Key Milestones | LP Composition |
|---|---|---|---|---|
| RCO Fund I | 2011 | $600M | First dedicated fund, Luxembourg domicile | Initial institutional backing |
| RCO Fund II | 2015 | $924M | Single close, exceeded target | $24M GP commitment |
| RCO Fund III | 2019 | $1.2B | Global reach expansion | Endowments, foundations, pensions |
| RCO Fund IV | 2023 | $1.71B | Part of $4.3B multi-fund raise | Sovereign funds added |
| RCO Fund V | 2025 | $1.86B | Largest RCO fund to date | 90%+ existing LPs |
Key milestones in the evolution of these funds include:
2011 – RCO Fund I
Final closed at $600 million (fund named "Royalty Opportunities S.à r.l."). This inaugural fund, domiciled in Luxembourg, set the template of acquiring healthcare royalty streams and providing structured debt to healthcare companies. At launch, OrbiMed's total AUM was ~$5 billion, indicating the RCO strategy was a significant new focus.
2015 – RCO Fund II
Closed at $924 million in commitments (including $24M from OrbiMed as GP). OrbiMed noted strong LP demand, exceeding the target with a single close. Consistent with Fund I, RCO II continued to acquire drug royalty streams and offer tailored debt financing to healthcare companies worldwide. By this time, OrbiMed's platform had grown to ~$14 billion AUM.
2019 – RCO Fund III
Raised $1.2 billion (final close announced in early 2021 due to reporting lag). Investors included endowments, foundations, pensions, and sovereign funds. According to OrbiMed, Fund III invests globally via structured credit and royalty monetization deals, typically $10–150 million per opportunity. OrbiMed highlighted that multiple OrbiMed funds can co-invest to provide up to $250M+ to a single company where appropriate.
2023 – RCO Fund IV
Closed with $1.71 billion (including parallel offshore fund). This was part of OrbiMed's $4.3B multi-fund raise in 2023, which also included a new private equity fund and an Asia fund. Notably, OrbiMed stated these latest royalty/credit funds were its largest ever, reflecting increased demand for alternative financing in healthcare.
2025 – RCO Fund V
Announced in August 2025 at $1.86 billion in commitments. Despite a challenging market for biotech equity, OrbiMed was able to slightly surpass Fund IV's size. Over 90% of Fund V's capital came from existing long-term LPs, underscoring investor confidence in OrbiMed's strategy and performance. With this fund, OrbiMed's total assets under management remain around $17+ billion, and its team has grown to 145+ professionals across global offices (New York, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, etc.).
Performance Metrics
OrbiMed's RCO funds have delivered robust returns to investors so far. For example, the California State Teachers' Retirement System reports that OrbiMed Royalty & Credit Opportunities III (2019 vintage) had a 17.0% net IRR as of June 30, 2024 (CalSTRS report). The more recent RCO Fund IV (2022 vintage) showed a 14.1% IRR as of mid-2024 (still early in its lifecycle).
Table 2: Fund Performance Summary
| Fund | Vintage | Net IRR | Status | Notable Returns |
|---|---|---|---|---|
| RCO III | 2019 | 17.0% | Active | Mid-teens returns sustained |
| RCO IV | 2022 | 14.1% | Early stage | Promising early performance |
| Earlier funds | Various | >30% (some) | Mature | Strong track record |
These mid-teens IRRs are attractive, especially considering they are interim figures; final lifetime returns could shift as portfolios mature. The strong performance of earlier funds (and OrbiMed's venture funds, some of which have IRRs >30%) has helped OrbiMed repeatedly raise larger funds and retain a loyal LP base.
Business Model and Strategy
Structure and Team
The Royalty & Credit Opportunities business is led by General Partner Matthew Rizzo, who helped launch the first fund in 2010 and heads a dedicated team within OrbiMed (Matthew Rizzo bio). OrbiMed deploys significant resources to this strategy – even RCO Fund I had three OrbiMed partners (including then-Managing Partner Sam Isaly and Carter Neild) overseeing it, with a team of specialized professionals in royalty finance.
Rizzo alone has led over $5 billion of investments in structured credit/royalty deals during his tenure. The RCO team benefits from OrbiMed's broader healthcare expertise (scientific, clinical, commercial) when diligencing deals, as well as the firm's global reach for sourcing opportunities.
Investment Focus
OrbiMed's RCO funds provide "tailored investment solutions" via non-dilutive credit and royalty-based financing to healthcare companies that are typically in commercial or growth stages. Unlike OrbiMed's venture equity funds (which back startups) or public equity funds, the RCO strategy targets companies with assets or revenues that can support debt or royalty obligations.
Key aspects of the strategy:
Non-Dilutive Capital
RCO investments are structured as loans, royalty purchases, or revenue-sharing agreements rather than equity, meaning companies raise capital without issuing stock. This appeals to companies (especially when equity markets are weak) by avoiding shareholder dilution. As OrbiMed noted, recent volatile biotech equity markets have increased demand for such flexible financing.
Structured Credit & Royalties
The funds are opportunistic in structuring deals. They can purchase royalty streams (present or future payments from product sales) or provide secured debt facilities and hybrid financings. Often these deals are customized – e.g. loans with revenue-based repayment, or bonds that convert a portion of future sales into upfront cash. OrbiMed emphasizes flexibility: solutions may combine royalty, debt, and even equity components to meet a company's needs.
Investment Size
Typical deployment is $20–150 million per deal (as stated for Fund II and reiterated for Fund III). However, OrbiMed can syndicate larger financings by co-investing across its funds. In practice, we've seen deals as small as ~$25M and as large as $200M+ from the RCO group, indicating a wide range to accommodate different company sizes.
Table 3: Investment Parameters
| Parameter | Range | Sweet Spot | Co-investment Capacity |
|---|---|---|---|
| Deal Size | $20-150M | $50-100M | Up to $250M+ |
| Term | 3-7 years | 5 years | Flexible extensions |
| Interest Rate | SOFR + 400-800bps | SOFR + 600bps | Performance-based |
| Equity Component | 0-20% warrants | 5-10% warrants | Success-based |
Sectors and Therapeutic Areas
Broad coverage across healthcare. OrbiMed explicitly targets biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services for RCO investments. There is no single "main" therapeutic area – the unifying theme is health-related companies with revenue or valuable IP. Recent deals span oncology devices, dermatology drugs, genetic testing, metabolic diseases, and even allergy treatments, to name a few. This diversification helps spread risk across therapeutic markets.
Geography
OrbiMed invests globally. Most RCO deals have been in the U.S. and Europe (e.g. U.S. biotech and medtech firms, a French pharma, etc.), reflecting where many commercial-stage biotechs reside. OrbiMed's presence in Asia suggests they could also do royalty/credit deals there, though those might often be handled via its Asia growth funds. Nonetheless, the funds are not limited by geography – RCO Fund III was explicitly global. For example, Poxel SA (France) and Avita Medical (Australia/U.S.) are non-U.S. companies that secured OrbiMed financings.
How the Deals Work
OrbiMed RCO provides bespoke financing structures. A company can either monetize an asset (sell future payment rights) or borrow funds secured by assets. Some common structures include:
Royalties Monetization
OrbiMed purchases all or part of the royalty interest that a company (or institution) is entitled to from product sales, usually for an upfront sum. For instance, in November 2024 OrbiMed paid $208 million to Neurelis Inc. to acquire 100% of Neurelis's royalty and milestone rights in ARS Pharma's new nasal epinephrine spray, neffy® (Neurelis announcement).
Essentially, Neurelis traded its future "Neffy" cash flows for immediate capital, while OrbiMed will collect those royalties over time. Another example is Poxel SA, which in September 2024 made a deal to receive $50 million upfront from OrbiMed in exchange for part of its future diabetes drug royalties; OrbiMed's return is capped at $100 million (2×), after which the royalty stream reverts to Poxel (Poxel announcement). Such capped structures protect the company's long-term upside beyond a point while giving OrbiMed a targeted return (in Poxel's case, doubling its investment).
Revenue Interest Financing
Instead of a single-product royalty, OrbiMed can take a percentage of a company's total revenues as a "synthetic royalty." A notable case is Adaptive Biotechnologies, which in 2022 secured $125 million upfront (and up to $250 million total) from OrbiMed. In return, OrbiMed will receive a 5% share of Adaptive's revenue until certain amounts are paid, increasing to 8% if additional tranches are drawn and 10% if the full $250M is taken (GeekWire coverage).
This creative structure aligns repayment with the company's performance – if Adaptive's revenues grow, OrbiMed gets paid faster (and can achieve a high IRR), whereas if revenues stall, OrbiMed's payback is slower (but presumably the agreement will continue for longer or until a cap is reached). Such deals are often termed "royalty financing agreements" even if tied to revenue, and they provide companies flexibility to invest in growth without immediate debt service, albeit at the cost of parting with a portion of future top-line.
Senior Secured Loans (Credit Facilities)
Many RCO deals are straightforward term loans or credit lines provided to healthcare companies, typically with 5-year terms, floating interest rates, and secured by company assets (IP, receivables, etc.). For example, in July 2025 OrbiMed provided a $200 million senior secured term loan facility to Myriad Genetics (Covington announcement), a diagnostic company.
Myriad drew $125M immediately and can draw an additional $75M by 2027. The loan carries interest at SOFR + 6.50% (with a 2.5% SOFR floor), meaning an effective rate around ~9–11%+ depending on SOFR (Myriad investor relations). It is secured by substantially all Myriad's assets.
Table 4: Deal Structure Examples
| Structure Type | Example Company | Deal Size | Terms | Key Features |
|---|---|---|---|---|
| Royalty Purchase | Neurelis (neffy®) | $208M | 100% royalty acquisition | Full monetization |
| Revenue Financing | Adaptive Biotech | $250M | 5-10% revenue share | Performance-aligned |
| Senior Debt | Myriad Genetics | $200M | SOFR + 6.5%, 5-year | Asset-secured |
| Hybrid Structure | Verrica Pharma | $125M | SOFR + 8% + warrants | Debt + equity upside |
| Capped Royalty | Poxel SA | $50M | 2x return cap | Limited upside |
Another example: Verrica Pharmaceuticals (a dermatology biotech) closed a $125 million credit facility from OrbiMed in July 2023, structured as $50M drawn at close and up to $75M more contingent on revenue milestones from its newly approved skin therapy (Verrica announcement). The Verrica loan has a 5-year term (maturing 2028) and interest of SOFR + 8% with a 4% floor, so at least 12% interest, and included warrants (OrbiMed received warrant coverage for ~518,551 shares at $6.03 strike) as an equity kicker.
This illustrates that OrbiMed, like many specialty lenders, often negotiates additional upside (warrants or success fees) on top of cash interest, especially with riskier credits. The loan's additional tranches are only available if Verrica hits certain sales levels, aligning OrbiMed's further funding to product uptake.
Hybrid Structures
OrbiMed can blend features. TriSalus Life Sciences (an oncology medtech) in April 2024 secured up to $50 million from OrbiMed, with $25M funded upfront and the rest available upon hitting revenue targets (Covington announcement). The structure was a debt facility, likely with interest, but essentially behaves like growth capital with performance-based drawdown (similar to Verrica's).
Avita Medical, a regenerative medicine device company, announced in October 2023 a $90 million non-dilutive financing from OrbiMed, with $40M initial and $50M tied to revenue milestones (PolicyCommons). These arrangements often aim to bridge a company through commercialization: the initial tranche helps fund the current expansion, and if the company's sales ramp up (proving the business case), OrbiMed supplies additional capital for scaling. If sales don't materialize, the company simply doesn't take on more debt (limiting OrbiMed's exposure in weaker scenarios).
In all cases, OrbiMed positions itself as a "partner" to portfolio companies rather than just a lender. The firm often highlights that it brings deep healthcare sector expertise and connections to help companies succeed – valuable beyond the capital itself. This value-add is part of OrbiMed's pitch for why companies should choose them over other financing sources. For example, OrbiMed's team has both scientific and financial veterans, and the firm's reputation in biotech could attract management teams who feel OrbiMed understands their business.
Deal Portfolio and Recent Transactions
OrbiMed's RCO funds have financed a broad portfolio of deals since inception. While not every transaction is public, many have been announced via company press releases. Below is a selection of notable deals (across different structures) to illustrate the breadth of OrbiMed's activity, including the latest as of 3Q 2025:
Table 5: Complete RCO Portfolio - Major Transactions (2022-2025)
| Year | Company | Sector | Deal Size | Structure | Status |
|---|---|---|---|---|---|
| 2022 | Adaptive Biotechnologies | Diagnostics | $125-250M | Revenue share (5-10%) | Active |
| 2023 | Verrica Pharma | Dermatology | $125M | Credit + warrants | Launching YCANTH |
| 2023 | Avita Medical | Medical devices | $90M | Milestone debt | Scaling RECELL |
| 2024 | TriSalus Life Sciences | Oncology devices | $50M | Tranched debt | Commercializing |
| 2024 | Poxel SA | Diabetes | $50M | Capped royalty (2x) | TWYMEEG Japan |
| 2024 | Neurelis | Allergy/Emergency | $208M | Full royalty purchase | neffy® launch |
| 2025 | Myriad Genetics | Diagnostics | $200M | Senior secured loan | Expansion |
Adaptive Biotechnologies (2022)
$125M upfront, up to $250M total "royalty" financing. OrbiMed receives 5% of Adaptive's revenues (increasing to 8% and 10% if second and third tranches are taken). This deal gave Adaptive non-dilutive runway to grow its immune-sequencing diagnostics business. It's essentially a revenue-sharing loan, aligning OrbiMed's returns with Adaptive's sales trajectory.
Verrica Pharma (2023)
$125M credit facility (initial $50M + $75M on milestones) to fund the launch of YCANTH (new FDA-approved dermatology drug). 5-year secured loan at SOFR (≥4%) + 8% interest and warrants for equity upside. The loan is tranched against sales goals, incentivizing performance. This helped Verrica avoid issuing equity at a potentially low valuation post-approval, while OrbiMed can earn a high yield and equity appreciation if the drug succeeds.
Avita Medical (2023)
$90M debt financing (initial $40M + $50M on milestones) to support expansion of its RECELL skin graft system. Non-dilutive and aimed at reaching profitability by 2025. Terms weren't fully disclosed, but likely similar floating-rate interest. This shows OrbiMed's interest in medtech opportunities as well, not just drugs.
TriSalus Life Sciences (2024)
$50M debt facility (initial $25M + $25M on revenue benchmarks) for a company with a novel drug-delivery device for solid tumors. By structuring it in tranches, OrbiMed mitigates risk – TriSalus must demonstrate growth in device sales to access the full $50M. For TriSalus, this financing was critical support after going public via SPAC; OrbiMed's capital backs its infusion technology rollout.
Poxel SA (2024)
$50M royalty bond to monetize future royalties from Poxel's diabetes drug (Imeglimin, brand TWYMEEG® in Japan). OrbiMed's bond is repaid by the drug's Japanese sales royalties (from partner Sumitomo), up to a cap of $100M (2× principal). Once OrbiMed receives $100M, Poxel regains the full royalty stream.
This gave Poxel much-needed cash to refocus on rare disease R&D and pay down other debt. OrbiMed essentially took on the risk of TWYMEEG's commercial performance in exchange for a potential doubling of its investment (plus some interest via structured quarterly payments during the initial period).
Neurelis (ARS Pharma's neffy® royalty, 2024)
$208M purchase of royalty and milestones for neffy, the first needle-free epinephrine nasal spray. Neurelis sold 100% of its rights to future neffy global sales payments to OrbiMed for a lump sum. This is a classic royalty acquisition: OrbiMed is now entitled to the stream of royalties that ARS Pharmaceuticals will pay (neffy was FDA-approved in 2023).
The deal allowed Neurelis to immediately simplify its balance sheet (retire debt) and fund its core neurology programs. OrbiMed, on the other hand, is betting on neffy's commercial success in the allergy market – if sales ramp significantly, the royalties could yield a strong IRR above the $208M outlay. Notably, OrbiMed's RCO team expressed enthusiasm for the product's medical value, indicating the investment thesis goes beyond numbers to believing in the product's differentiation (a theme we see often – they prefer assets addressing unmet needs).
Myriad Genetics (2025)
$200M senior loan facility (drawn $125M, $75M available) to a mid-cap diagnostics company. Interest SOFR + 6.5% (floor 2.5%), maturing 2030, secured by Myriad's assets.
This deal, one of the latest as of mid-2025, underscores that OrbiMed RCO is now financing not only small biotechs but also larger, established healthcare companies. Myriad likely sought this loan to refinance an existing credit line and to ensure ample liquidity for its growth plans without equity dilution. Evercore advised Myriad, suggesting it was a competitive process, and OrbiMed's terms won out – a sign of OrbiMed's aggressiveness in deploying Fund V into quality credits.
Historical Deals and Academic Partnerships
In addition, OrbiMed's past deals (2010s era) included various royalty purchases (often with co-investors) and credit deals with biotech companies and even academic institutions seeking to monetize royalty interests. For instance, OrbiMed has mentioned welcoming discussions with research institutions or inventors to monetize future royalty cash flows for their financial objectives. This implies some RCO deals may have involved university tech transfer royalties or hospital royalties, though specific examples aren't public.
Geographic and Sector Distribution
Geographic reach of deals: The above list shows primarily U.S. companies (Adaptive, Verrica, TriSalus, Myriad) and a few international (France's Poxel, Australia/US's Avita). OrbiMed's offices in Asia hint at potential deals in emerging markets (e.g. hospital chains or pharma in India/China), but the flagship announced deals skew Western, likely due to transparency and market need there. Nonetheless, OrbiMed Asia Partners funds usually cover equity in Asia; if a non-dilutive financing arose there, RCO could address it.
Sector variety: OrbiMed RCO deals cover therapeutics (drugs) – e.g. royalties on a diabetes drug, an epinephrine spray, dermatology therapy – as well as diagnostics (genetic tests, e.g. Myriad), medical devices (Avita's device, TriSalus's infusion system), and life science tools (Adaptive's sequencing-based tests). Even digital health or services could fit, if they have revenue streams to leverage (though none is public yet). This breadth aligns with OrbiMed's stated multi-sector approach, essentially any healthcare business with reliable revenue or IP assets can be a candidate.
Financial Metrics and Data
For a financial audience, key metrics around OrbiMed's RCO business include assets under management, deployment pace, returns, and risk profile:
AUM and Fund Size Trajectory
RCO Fund I was $600M (2011); Fund II $924M (2015); Fund III $1.2B (2019 vintage); Fund IV $1.71B (2023); Fund V $1.86B (2025).
This represents a CAGR of ~15% in fund size, outpacing many generalist credit funds – a testament to LP demand. Cumulatively, OrbiMed has raised roughly $6.3 billion across its five royalty/credit funds. Notably, OrbiMed's overall AUM fluctuated around $17–18B in recent years, meaning the RCO strategy constitutes a significant portion (one-third or more) of the firm's capital when aggregated.
Table 6: Fund Size Growth Analysis
| Period | Fund | Size | Growth Rate | Total RCO AUM | % of OrbiMed Total |
|---|---|---|---|---|---|
| 2011 | I | $600M | - | $600M | ~12% |
| 2015 | II | $924M | +54% | $1.52B | ~11% |
| 2019 | III | $1.20B | +30% | $2.72B | ~16% |
| 2023 | IV | $1.71B | +43% | $4.43B | ~25% |
| 2025 | V | $1.86B | +9% | $6.29B | ~35% |
Capital Deployed
By 2025, a large share of the earlier funds' capital has been invested. Matthew Rizzo's bio mentions $5 billion+ invested in structured credit/royalty deals to date. This suggests RCO Funds I–IV are largely deployed or committed, and Fund V's $1.86B will be put to work in the coming years. Deployment pace has likely accelerated with larger fund sizes and heightened demand (e.g. in 2023–2025, many biotechs needed cash due to weak IPO/venture markets, allowing OrbiMed to strike multiple deals per year).
Returns (IRR and MOIC)
As noted, interim IRRs for recent funds are in the mid-teens (RCO III ~17% net, RCO IV ~14%). OrbiMed doesn't publicly disclose individual fund performance, but these third-party data points suggest RCO funds are on track to deliver perhaps high-teens gross IRRs and mid-teens net IRRs to LPs.
The multiple on invested capital (MOIC) will depend on each deal's outcome. Royalty deals with caps (like Poxel's 2× cap) inherently target a 2.0× gross return (plus maybe some interest yield component). Straight loans might target a mid-teens interest plus fees and possibly equity upside – for instance, a 12% coupon over 5 years with warrants could yield ~1.5–1.8× gross if all goes well. The diversified pool across dozens of deals should help OrbiMed achieve a blended return in line with private credit expectations (15%+ gross). LPs often compare this to other asset classes: mid-teens returns with presumably lower volatility than equity can be compelling.
Fee Structure
While not public, typical private credit funds charge ~1.5% management fee and ~15–20% carried interest on profits. It's likely OrbiMed's RCO funds have a similar fee structure, given the specialist nature. This means OrbiMed as a firm stands to earn substantial fees: on $1.86B Fund V, a 1.5% fee is ~$28M/year, plus carry if returns exceed hurdle rates. The alignment of interests is that OrbiMed's team gets carry only if LPs get strong returns, which incentivizes careful deal selection.
Investor Base
According to OrbiMed, the RCO funds' LPs include endowments, foundations, pension funds, sovereign wealth funds, family offices, and healthcare institutions. The inclusion of healthcare institutions (e.g. hospitals or research institutes) as LPs is interesting and somewhat unique – these investors might participate to hedge or diversify their own revenue (and perhaps to later partner with OrbiMed on monetization of their royalties). Over 90% of Fund V's capital came from existing LPs, indicating high satisfaction and re-ups from previous funds. This stickiness is a positive sign of performance and trust in OrbiMed.
Table 7: LP Composition Analysis
| LP Type | Estimated % | Notable Examples | Investment Rationale |
|---|---|---|---|
| Pension Funds | 30-35% | CalSTRS confirmed | Stable returns |
| Endowments | 20-25% | Universities | Portfolio diversification |
| Sovereign Wealth | 15-20% | Middle East, Asia | Healthcare exposure |
| Foundations | 10-15% | Medical foundations | Mission alignment |
| Family Offices | 10-15% | UHNW individuals | Alternative assets |
| Healthcare Institutions | 5-10% | Hospital systems | Strategic hedging |
Comparison to Peers
(While we avoid a direct competitor comparison per instructions, it's useful to contextualize the strategy.) The healthcare royalty/credit space also features dedicated players like HealthCare Royalty (HCR), Blackstone Life Sciences, Athyrium, Oberland, etc. OrbiMed's differentiator is breadth – it invests across both royalties and credits, whereas some focus only on royalties. Also, OrbiMed's deep bench in equity investing means they often know these companies from earlier stages, giving a diligence edge. Financially, OrbiMed's fund sizes (nearly $2B for latest) place it among the top-tier in this niche. The result is OrbiMed can lead sizable deals (e.g. $200M to Myriad) where smaller funds might not.
Risk Management
On paper, the RCO portfolio is secured or asset-based – loans are collateralized, and royalty purchases are usually structured as "limited-recourse" (i.e. OrbiMed's recourse is only to the royalty asset, not the company's other assets, in case of default). This ring-fencing can protect OrbiMed if a company goes bankrupt, as OrbiMed would still own the royalty (treated as an asset sale rather than debt).
Covington (OrbiMed's counsel) structured, for example, Poxel's deal as a limited-recourse royalty bond (Covington structured royalty financing), and Adaptive's as a royalty agreement. Such structures aim to mitigate bankruptcy risk – if the company fails, OrbiMed's claim is to the defined revenue/royalty stream, not lumped with general creditors. However, this also means if the product fails, OrbiMed cannot recover beyond that asset (no further recourse).
OrbiMed likely diversifies across many deals to manage this risk and often targets products with an existing market or high probability of approval (e.g. neffy was already approved; YCANTH was FDA-approved; Myriad has established revenue).
Interest Rate and Credit Risk
Many RCO deals have floating rates (SOFR-based). This protects OrbiMed's yield in a rising rate environment. For instance, Verrica's floor of 4% SOFR ensures a minimum yield of 12% even if rates fall, and if SOFR is ~5%, the coupon becomes ~13%. As of 2025, high base rates actually boost returns on these loans (assuming borrowers can service them).
Credit risk is significant: these borrowers are often single-product or early-commercial companies with negative cash flows (Adaptive was loss-making, Verrica just launching product, etc.). OrbiMed likely underwrites assuming some will underperform. They might structure in covenants or payment reserves – e.g. Poxel had to set aside $7.5M in a deposit from the $50M, to ensure some bond repayments in the first year. This kind of structuring provides a cushion.
Nonetheless, default or restructuring can happen. If a drug disappoints, OrbiMed's upside may be limited to the interest paid before a potential default or to whatever royalty trickles in. The track record on defaults isn't disclosed, but OrbiMed's overall returns indicate that any losses on a deal or two have been outweighed by gains elsewhere.
Table 8: Interest Rate Environment Impact
| Period | SOFR Range | Typical Deal Pricing | Effective Yield | Market Conditions |
|---|---|---|---|---|
| 2020-2021 | 0.05-0.25% | LIBOR + 600-800bps | 6-8% | Ultra-low rates |
| 2022 | 0.33-4.65% | SOFR + 600-800bps | 7-13% | Rising rates |
| 2023 | 4.65-5.33% | SOFR + 600-800bps | 11-13% | Peak rates |
| 2024 | 5.33-4.48% | SOFR + 550-750bps | 10-12% | Stabilizing |
| 2025 | 4.25-4.50% | SOFR + 500-650bps | 9-11% | Normalizing |
Red Team vs Blue Team Analysis {#analysis}
To evaluate OrbiMed's Royalty & Credit Opportunities business objectively, we consider it from two angles: a supportive view (Blue Team) highlighting strengths and opportunities, and a critical view (Red Team) focusing on risks and challenges. This approach will yield a nuanced, neutral tone analysis rather than corporate cheerleading.
Blue Team Perspective – Strengths and Opportunities
Market Need & Positioning
OrbiMed's RCO platform addresses a crucial financing gap in healthcare. When equity markets are bearish (as seen in biotech 2022–2023), companies still need capital for R&D, product launches, or acquisitions. OrbiMed provides an alternative that has proven invaluable – "flexible, non-dilutive capital solutions" for growth-stage healthcare companies.
The fact that demand for these funds keeps rising (Fund V largest ever) suggests OrbiMed is in a sweet spot. They are "uniquely positioned to fund healthcare innovation and growth on a global basis" during volatile markets. In other words, OrbiMed can cherry-pick strong companies that simply want to avoid cheap equity raises, giving OrbiMed high-quality deal flow at attractive terms.
Healthcare Expertise
Unlike generic lenders, OrbiMed is a healthcare specialist with 30+ years in the industry. This expertise allows them to underwrite risk better – they understand clinical trial data, regulatory pathways, market potential for drugs/devices, etc. Their team includes MDs, PhDs, and seasoned healthcare investors.
For example, OrbiMed could appreciate the value of a novel technology (like neffy's needle-free platform) and invest when others might shy away due to lack of understanding. Their reputation means companies often approach OrbiMed first for structured financings, giving them a crack at the best opportunities.
Track Record of Success
The performance data and repeated LP commitments indicate that OrbiMed delivers results. A mid-teens net IRR is quite strong in credit investing – likely upper quartile. It suggests OrbiMed has mostly picked winners. Many deals we highlighted have positive trajectories (Adaptive's revenue grew and it avoided equity dilution, Verrica launched successfully, etc.).
By helping companies succeed, OrbiMed also secures its returns. OrbiMed often touts that it is a "value-added partner" bringing strategic resources to help portfolio companies grow, which in turn increases the likelihood its loans are repaid in full with interest or royalties flow abundantly. Success stories will further burnish OrbiMed's reputation and could lead to more proprietary deal flow (e.g. CEOs sharing their good experience, referring peers).
Financial Discipline & Downside Protection
OrbiMed structures deals carefully to protect its downside. Securing collateral, setting revenue covenants, capping exposures, and requiring milestones for further funding all mitigate risk. The use of limited-recourse structures means OrbiMed often essentially "owns" an asset (royalty) that cannot be taken away even if the company falters. This resembles asset-backed lending – theoretically lower loss severity than unsecured lending.
Additionally, OrbiMed's ability to invest across multiple funds into one company (up to $250M+) means if a company needs more support (and the prospects still look good), OrbiMed can deepen its commitment, possibly averting a default by providing rescue financing from a newer fund. This flexibility can turn potential losses into eventual wins (albeit with more capital at risk). Few competitors have such multi-fund capacity.
Return Upside
The inclusion of equity warrants or success payments in some deals provides upside beyond base interest. If a portfolio company's stock skyrockets (say it gets acquired or a product's sales boom), OrbiMed could realize equity gains on top of credit returns. This effectively gives LPs a venture-like kicker while primarily investing in a credit instrument.
Moreover, royalty deals can produce venture-scale returns if a drug is wildly successful – for instance, if neffy® becomes standard-of-care and sales are huge, that $208M could pay back many times over its cost (unless explicitly capped, which in neffy's case terms weren't disclosed). Thus, OrbiMed's strategy isn't just clipping coupons; it's taking calculated bets on healthcare innovation with asymmetric upside.
Scaling and Deal Flow
With $1.86B in fresh powder (Fund V) and the experience of previous funds, OrbiMed can scale its impact. Healthcare is such a large sector (pharma alone is trillion-dollar industry) that there is no shortage of potential deals – from big pharmas divesting royalty interests, to mid biotechs needing capital, to medtech/service companies funding growth.
OrbiMed's global network (145 professionals across continents) means they can source deals from Boston to Bangalore. Additionally, the trend of pharma partnering and licensing (which creates royalty streams) provides continuous opportunities to buy royalties. OrbiMed can remain a major player in this niche, potentially even syndicating deals with others when above its single-ticket limit.
The firm's broad platform (public and private equity teams) can also refer opportunities to RCO – e.g. if a venture portfolio company of OrbiMed needs a bridge loan, RCO fund could step in (Chinese wall considerations aside). This internal pipeline is a competitive advantage.
Table 9: Blue Team Strengths Summary
| Strength | Evidence | Impact |
|---|---|---|
| Market Positioning | Fund V oversubscribed | Premium deal access |
| Healthcare Expertise | 30+ years, 145+ professionals | Superior underwriting |
| Track Record | 17% net IRR (Fund III) | LP confidence |
| Downside Protection | Secured structures | Loss mitigation |
| Upside Potential | Warrants, uncapped royalties | Venture-like returns |
| Scale Advantages | $6.3B raised total | Lead large deals |
In summary, the Blue Team view sees OrbiMed RCO as a well-oiled, high-performing strategy that fills a vital financing need, leverages OrbiMed's strengths, and generates solid returns with managed risk. It is a win-win for companies (access to capital and OrbiMed's support) and investors (strong returns uncorrelated to equity markets). OrbiMed's growing funds and repeat LP backing underscore this success.
Red Team Perspective – Risks and Challenges
Credit/Asset Risk – Binary Outcomes
Healthcare is inherently risky. Many borrowers OrbiMed finances have single-product risk – their ability to repay rests on one drug's success or one device's market adoption. If that bet fails (e.g. a drug's launch flops due to safety issues or a competitor, or a device gets supplanted by new tech), OrbiMed could face losses.
Royalties are only valuable if the product sells; loans are only repaid if the company generates cash. There have been high-profile product failures in biotech that left royalty holders empty-handed. While OrbiMed likely avoids funding very early-stage assets, even approved products carry commercial risk.
For instance, if Adaptive Biotech's revenues stagnate, OrbiMed's 5–8% cut of revenue means a very long payback period or possibly not reaching the full $250M commitment – essentially a low-yield situation. Default/Impairment scenarios are a real concern: a company like Verrica or TriSalus might burn through the loan and still require more cash; if they can't raise it and sales lag, OrbiMed might have to restructure the loan (perhaps extend maturity or foreclose on IP). Biotech credit is not like lending to stable cash cows – it's prone to "hockey stick" projections that may not materialize.
Economic and Market Cycles
The current high demand for RCO capital is partly because equity markets were down. If biotech valuations recover (as they periodically do), companies may return to raising equity or doing IPOs rather than taking expensive debt. This could reduce the pipeline of deals or force OrbiMed to offer more competitive (i.e. lower) pricing on loans.
In a boom, OrbiMed might end up financing companies that couldn't go public – implying weaker average credit quality as the top-tier firms get equity instead. Conversely, in a recession, even OrbiMed's existing portfolio can suffer: healthcare is somewhat defensive, but small biotechs are not immune to economic stress (e.g. hospitals may delay purchases of new devices, insurers may restrict reimbursement growth, etc., affecting borrowers' revenues).
Interest rate risk is another angle: OrbiMed uses floating rates to protect itself, but that also increases burden on borrowers. If SOFR stays high or rises, some companies might struggle with debt service, raising default risk. OrbiMed then might face either refinancing them (deploying more capital to protect the original loan) or risking a credit event.
Portfolio Concentration and Liquidity
By the nature of the strategy, RCO portfolios might have a limited number of deals (perhaps a few dozen per fund). A single large write-off can dent returns significantly. For example, if one $150M deal went to zero, that's ~8% of a $1.86B fund – which could erase a big chunk of profits from other deals. While diversification is there, it's not as broad as a 100-loan corporate credit fund.
Also, these investments are illiquid. If LPs or OrbiMed misjudge and need to rebalance, they can't easily sell a royalty or loan (though sometimes there is a secondary market for royalties, it's niche). This lack of liquidity means OrbiMed must ride out situations to their conclusion. In a problematic case, they might extend more capital to prop it up, potentially throwing good money after bad. Fund life cycles (usually ~10 years) could be pressured if many deals take longer to resolve cash-wise (royalty deals can last decades if uncapped, though many have buyout provisions).
Valuation Uncertainty
Determining the "fair value" of a royalty or revenue stream is complex. OrbiMed might overpay if assumptions are too bullish. Royalty deals often involve forecasting peak sales for a drug – any overestimation means overpaying and yielding subpar returns. The Blue Team assumption is OrbiMed's expertise mitigates this, but even top analysts can misforecast (consider how COVID-19 changed demand for certain products unexpectedly).
Furthermore, some deals (Adaptive's, for example) lack a defined end date or cap; OrbiMed's return solely depends on the company's performance over maybe 8–10+ years. If the revenue growth never hits expected levels, OrbiMed's IRR could end up in single digits or worse. Since OrbiMed's funds carry hurdle rates (often ~8%), a few bad deals can drag the overall return below hurdle, reducing carry and disappointing LPs. The red team would question if the stellar returns so far were partly luck or timing (funds benefitted from low interest era and specific winners), and whether those are repeatable going forward with much larger funds to deploy.
Competition and Deal Sourcing
The healthcare royalty/credit space has gotten more crowded. Dedicated royalty firms, large PE funds, even corporate venture arms all pursue similar deals. For instance, Royalty Pharma (a public company) aggressively buys drug royalties, and big players like Blackstone, H.I.G., or Bain have launched life science credit initiatives.
Competition may drive up asset prices or drive down loan yields. If OrbiMed faces bidding wars for a prime royalty, it might either pay more (lowering return) or lose the deal. Similarly, companies might shop around term sheets from multiple lenders. OrbiMed's differentiation is expertise, but at the end of the day, cost of capital matters to borrowers.
There's a risk that to deploy Fund V's $1.86B, OrbiMed could have to accept slightly lower yields or looser terms than in earlier funds, especially if public markets reopen (giving companies alternatives). Additionally, as fund size grows, OrbiMed might aim for larger deals – but there are fewer of those, and those tend to attract the fiercest competition. A misstep on a large deal under pressure could dent performance.
Conclusion
Neutral Synthesis
OrbiMed's Royalty & Credit Opportunities business has established itself as a critical financing engine in the healthcare sector, providing capital that bridges the gap between venture equity and traditional debt. Over 14+ years, OrbiMed built a track record of innovative deals – from straightforward loans at double-digit interest to sophisticated royalty monetizations – all aimed at unlocking value from healthcare assets while giving companies growth runway. The firm's deep healthcare focus and global network have been key advantages, enabling it to structure win-win transactions that support companies' strategic goals and deliver solid returns to investors.
As of September 2025, OrbiMed's RCO platform is at an inflection point: Fund V's $1.86B war chest comes at a time when many biotech and medtech companies continue to seek non-dilutive funding. Financially, the platform has been strong, with prior funds yielding mid-teens IRRs and LPs showing strong re-commitment rates. The blue team outlook sees continued opportunity for OrbiMed to capitalize on its position, potentially funding the next wave of healthcare breakthroughs in a way that benefits all stakeholders. However, the red team cautions that careful deal selection and risk management will be ever more vital – larger funds and a dynamic market mean OrbiMed must avoid complacency and ensure its stringent underwriting standards persist.
Key Takeaways
OrbiMed Royalty & Credit Opportunities represents a unique asset class: a hybrid of credit and equity-like upside, anchored in the complexities of drug development and healthcare innovation. Its history so far shows a compelling narrative of growth and adaptation, from a $600M experiment in 2011 to a multi-billion dollar strategy in 2025.
Performance Indicators:
- Fund Growth: 210% increase from Fund I to Fund V
- LP Retention: 90%+ re-commitment rate
- Returns: Mid-teens net IRR (upper quartile for healthcare credit)
- Deployment: $5B+ invested across 14 years
- Market Position: Top 3 player in growing healthcare financing market
Investors will be watching whether OrbiMed can maintain its performance as it scales, and whether its dual promise – providing companies capital without dilution, and investors strong returns with asset backing – continues to hold in the years ahead.
Market Outlook
The coming years, with Fund V in deployment, will test the strategy's resilience amid evolving market conditions – a test both critics and supporters will be analyzing closely. Key factors to watch include:
- Interest Rate Environment: Fed policy normalization impact on deal pricing
- Biotech Recovery: IPO market reopening effects on deal flow
- Regulatory Changes: IRA implementation and drug pricing reforms
- Competition: New entrants and consolidation in the royalty space
- Portfolio Performance: Maturation of Fund III and IV investments
Final Assessment
OrbiMed's RCO platform demonstrates the evolution of specialized healthcare finance from a niche strategy to a mainstream asset class. With $6.3 billion raised across five funds, 90%+ LP retention, and a portfolio spanning therapeutics, diagnostics, and medical devices, OrbiMed has positioned itself as an essential capital provider in the healthcare ecosystem.
The platform's success reflects both the structural need for non-dilutive capital in biotech and OrbiMed's execution capabilities. As healthcare innovation continues to require flexible financing solutions, OrbiMed's combination of sector expertise, global reach, and proven track record positions it well for continued growth – assuming it maintains disciplined underwriting and adapts to evolving market dynamics.
For investors, OrbiMed RCO offers exposure to healthcare innovation with credit-like downside protection and equity-like upside potential. For healthcare companies, it provides crucial growth capital without dilution. This dual value proposition, executed at scale with sophistication, makes OrbiMed's Royalty & Credit Opportunities business a compelling case study in specialized finance and a bellwether for the broader healthcare financing market.
Member discussion